Login to Your Account



Biogen and Abbott Start Phase III Trial of MS Antibody Daclizumab

By Trista Morrison


Tuesday, May 25, 2010
Biogen Idec Inc. and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription